Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Update

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 7,480,000 shares, an increase of 29.2% from the December 31st total of 5,790,000 shares. Based on an average trading volume of 1,410,000 shares, the short-interest ratio is currently 5.3 days.

Insider Activity

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $8.43, for a total value of $38,415.51. Following the completion of the sale, the director now directly owns 13,356 shares in the company, valued at approximately $112,591.08. This trade represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 4.30% of the stock is owned by company insiders.

Institutional Trading of Aurinia Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State Street Corp boosted its position in shares of Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after acquiring an additional 64,949 shares during the last quarter. Barclays PLC boosted its holdings in Aurinia Pharmaceuticals by 187.6% in the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after purchasing an additional 143,072 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Aurinia Pharmaceuticals in the 3rd quarter valued at approximately $3,330,000. SG Americas Securities LLC increased its holdings in shares of Aurinia Pharmaceuticals by 4,307.9% during the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after buying an additional 535,301 shares during the last quarter. Finally, Algert Global LLC lifted its holdings in Aurinia Pharmaceuticals by 106.8% in the second quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company’s stock valued at $1,107,000 after acquiring an additional 100,104 shares during the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 9th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Trading Down 2.4 %

Shares of NASDAQ AUPH opened at $7.76 on Monday. The stock has a market capitalization of $1.11 billion, a P/E ratio of -51.60 and a beta of 1.22. The business’s 50 day moving average is $8.68 and its two-hundred day moving average is $7.49. Aurinia Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $10.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.